Everest Medicines Limited (EVEREST MED) announced that substantial shareholder CBC Group, acting in concert with non-executive director and honorary chairman Wei Fu, purchased 679,000 ordinary shares on the open market between 8 June 2026 and 9 June 2026.
The transaction amounted to approximately HK$18.90 million, translating to an average acquisition price of HK$27.90 per share.
According to the filing, the additional stake reflects CBC Group’s and Wei Fu’s confidence in the company’s long-term prospects. The parties indicated that further share purchases may be considered, subject to regulatory compliance.
The board advised shareholders and potential investors to exercise caution when dealing in the company’s securities. The voluntary announcement was released on 10 June 2026.